Table 2.

The relationship between the expression of iNOS, VEGF, MVD and TNM staging of gastric carcinoma

Clinical staging	n	Expression of iNOS (%)	Expression of VEGF (%)	MVD (¯x ± s)
Stage I	2	1 (50.0)	1 (50.0)	51.00 ± 7.0d
Stage II	6	2 (33.33)	3 (50.0)	47.66 ± 8.71e
Stage III	25	13 (52.0)	19 (76.0)b	64.72 ± 14.96f
Stage IV	13	11 (84.62)a	12 (92.31)c	76.09 ± 18.29g

^aP < 0.05, (Fish exact probabilities test, P = 0.019, 0.023 and0.033), vs the rate of expression of iNOS in stage I, II and III, recpectively;

^bP < 0.05 (Fish exact probabilities test, P = 0.031 and 0.017), vs the rates of expression of VEGF in stage Iand II, recpectively;

^cP < 0.05 (Fish exact probabilities test, P = 0.022 and 0.019), vs the rates of expression of VEGF in stage I and II, recpectively;

^dP < 0.05 (t = 2.378, vs MVD in stage III;

^eP < 0.001 (t = 4.015), vs MVD in stage IV;

^fP < 0.001 (t = 2.503), vs MVD in stage II;

^gP < 0.05 (t = 2.450), vs MVD in stage I.